CA2944450C - Substituted cyclopenta pyrimidine bicyclic compounds having antimitotic and/or antitumor activity and methods of use thereof - Google Patents

Substituted cyclopenta pyrimidine bicyclic compounds having antimitotic and/or antitumor activity and methods of use thereof Download PDF

Info

Publication number
CA2944450C
CA2944450C CA2944450A CA2944450A CA2944450C CA 2944450 C CA2944450 C CA 2944450C CA 2944450 A CA2944450 A CA 2944450A CA 2944450 A CA2944450 A CA 2944450A CA 2944450 C CA2944450 C CA 2944450C
Authority
CA
Canada
Prior art keywords
substituted
compound
alkyl
carbon atoms
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2944450A
Other languages
English (en)
French (fr)
Other versions
CA2944450A1 (en
Inventor
Aleem Gangjee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duquesne University of the Holy Spirit
Original Assignee
Duquesne University of the Holy Spirit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/244,445 external-priority patent/US9624178B2/en
Application filed by Duquesne University of the Holy Spirit filed Critical Duquesne University of the Holy Spirit
Publication of CA2944450A1 publication Critical patent/CA2944450A1/en
Application granted granted Critical
Publication of CA2944450C publication Critical patent/CA2944450C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2944450A 2014-04-03 2015-03-27 Substituted cyclopenta pyrimidine bicyclic compounds having antimitotic and/or antitumor activity and methods of use thereof Active CA2944450C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/244,445 US9624178B2 (en) 2008-07-10 2014-04-03 Substituted cyclopenta pyrimidine bicyclic compounds having antitmitotic and/or antitumor activity methods of use thereof
US14/244,445 2014-04-03
PCT/US2015/022871 WO2015160489A2 (en) 2014-04-03 2015-03-27 Substituted cyclopenta pyrimidine bicyclic compounds having antimitotic and/or antitumor activity and methods of use thereof

Publications (2)

Publication Number Publication Date
CA2944450A1 CA2944450A1 (en) 2015-10-22
CA2944450C true CA2944450C (en) 2023-03-21

Family

ID=54324696

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2944450A Active CA2944450C (en) 2014-04-03 2015-03-27 Substituted cyclopenta pyrimidine bicyclic compounds having antimitotic and/or antitumor activity and methods of use thereof

Country Status (4)

Country Link
EP (1) EP3125897A4 (de)
JP (1) JP6532887B2 (de)
CA (1) CA2944450C (de)
WO (1) WO2015160489A2 (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57203072A (en) 1981-06-05 1982-12-13 Sankyo Co Ltd 4-anilinopyrimidine derivative, its preparation, antidepressant comprising it as active ingredient
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
AU2010339444A1 (en) 2009-12-30 2012-07-19 Arqule, Inc. Substituted pyrrolo-aminopyrimidine compounds
US9139590B2 (en) * 2011-02-04 2015-09-22 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient

Also Published As

Publication number Publication date
WO2015160489A2 (en) 2015-10-22
JP6532887B2 (ja) 2019-06-19
CA2944450A1 (en) 2015-10-22
JP2017512805A (ja) 2017-05-25
EP3125897A2 (de) 2017-02-08
WO2015160489A3 (en) 2016-03-31
EP3125897A4 (de) 2017-11-15

Similar Documents

Publication Publication Date Title
US11840539B2 (en) Substituted pyrrolo,-furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
US10676483B2 (en) Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
Ge et al. Synthesis and biological evaluation of 6-fluoro-3-phenyl-7-piperazinyl quinolone derivatives as potential topoisomerase I inhibitors
CA2944450A1 (en) Substituted cyclopenta pyrimidine bicyclic compounds having antimitotic and/or antitumor activity and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200317

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20240927